Heme Onc Flashcards
Lead poisoning
Affecting ferrochelatase and ALA dehydrase
(Heme synthesis starts w glycine and succinylCoA w cofactors B6 and delta ALA synthase)
Leads to accumulation of protoporphyrin and delta ALA
Cause microcytic anemia due to lack of heme
Also
Paroxysmal nocturnal hemoglobinuriA
Increased complement mediated RBC lysis due to impaired GPI anchor that protects RBC from complement
Located on X chromosome so only one copy of gene is active at a time
acquired mutation in hematopoietic stem cell leads to hemolysis
Hemophilia
Deficiency in intrinsic pathway
A: VIII, B: IX
Increases PTT
Vitamin K deficiency (warfin)
General coagulation defect
Decreases synthesis of 1972 C and S
Increased PTT and PT
Bernard Soulier syndrome
Defect in platelet plug formation
Decreased GpIb leading to defect in platelet vWF adhesion
Increased bleeding time, decreased platelet count
Glanzamann thrombasthenia
Defect in platelet plug formation
Decreased GpIIb/IIIa leading to decreased platelet to platelet aggregation
Increased bleeding time
Immune thrombocytopenia
Anti GpIIb/IIIa antibodies leading to macrophage destruction of platelet antibody complex
Decreased platelet survival
Thrombotic thrombocytopenia
Inhibition or deficiency of ADAMTS 13 leading to decreased degradation of vWF and unnecessary platelet aggregation and thrombosis
Decreased platelet survival time
Von Willebrand disease
Intrinsic pathway coagulation defect
Decreased vWF leading to decreased factor VIII and decreased platelet plug formation
Normal PT and increased PTT
Treat w DDAVP (desmopressin, releasing vWF from endothelium)
DIC
Widespread activation of clotting leading to deficiency in clotting factors
Caused by sepsis, trauma, malignancy, transfusion
Increased bleeding time, PT, PTT, decreased platelet count
Factor V Leiden
Production of mutant factor V that is resistant to degradation by activation of protein C
Most common cause of hypercoaguability
Hodgkin lymphoma
Localized single group of nodes, extra nodal rare
Contiguous spread
Constitutional B symptoms: low grade fever, night sweats, weight loss
Good prognosis
50 percent cases associated w EBV
Young adults and greater than 55
Non-Hodgkin lymphoma
Multiple peripheral nodes w extra nodal involvement common
Noncontiguous spread
Fewer constitutional symptoms
Peak incidence 20-40
May be associated w HIV and immunosuppression
Reed Steenberg cell
Tumor giant cell seen in Hodgkin lymphoma
Binucleated or bilobed w halves as mirror images (owl eye)
Better prognosis w strong stromal or lymphocytic reaction against RS cells
Burkett lymphoma
T(8;14) translocation of c-myc
Starry sky appearance
Associated with EBV
Diffuse large B cell lymphoma
T (14;18)
Most common type of non Hodgkin
Mantle cell lymphoma
T(11;14), translocation of cyclin D
Older males
Follicular lymphoma
T(14;18) w translocation of bcl-2 (inhibits apoptosis)
Acute lymphoblastic leukemia
Peripheral blood and bone marrow smear have greatly increased lymphoblasts (often around 20%)
T(12;21) better prognosis
Chronic lymphocytic leukemia
Progress slowly
Smudge cells
Autoimmune hemolytic anemia
Hairy cell leukemia
Stains w TRAP
Mature B cell tumor, cells have hair like projections
Acute myelogenous leukemia
Auer rods
T(15;17) M3 subtype responds to retinoids acid
DIC common presentation
Chronic myelogenous leukemia
T(9;22) Philadelphia chromosome bcr-abl
Increased neutrophils, metamylocytes, basophils
Can accelerate and transform to AML or ALL
Very low leukocyte alkaline phosphatase as opposed to leukemoid reaction
Responds to imatinib(inhibitor of bcr-abl kinase)
Langerhan cell histiocytosis
Proliferation disorder of dendritic cells in skin
Cells are immature and do not stimulate T cells
Cells express S-100
Present in children w bone lesions and recurrent otitis media
Argatroban
Anticoagulant used by leeches
Inhibit thrombin directly, use in patients for anticoagulantion after heparin induced thrombocytopenia
Rivaroxaban
Bind directly and inhibit activity of factor Xa
Treatment and prophylaxis of DVT and PE
Stroke prophylaxis for pts w afib
Clopidogrel
Inhibit platelet aggregation by irreversibly blocking ADP receptors and further activation of platelets by platelets (ADP binding promotes integration of GIIb/IIIa)
Cliostazol
Phosphodieserase III inhibitor
Increase cAMP in platelets thus inhibiting platelet aggregation
Methotrexate
Frolic acid analog
Decreased DNA synthesis due to decreased dTMP
5 fluorouracil
Pyrimidine analog covalently complexes folic acid
Decreases dTMP and decrease DNA synthesis